Cannabinoid Composition for Neuroinflammation Without Psychoactive Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved cannabinoid compositions and treatments for neurological disorders, particularly those that address neuroinflammation and its associated conditions, which current treatments are limited by psychomimetic effects, depressant side effects, and lack of efficacy.
Innovation Solution
A composition comprising about 50 w/w % of CBDA and up to 15 w/w % of other cannabinoids, including CBD, CBG, CBDP, CBDB, CBGA, and CBN, with THC at less than 1%, formulated to target neuroinflammation and provide therapeutic benefits without psychoactive effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cannabinoid treatments are used to address neurological disorders, then some therapeutic effects may be achieved, but psychomimetic effects and depressant side effects occur
Solution Approach 1:
The patent extracts and isolates specific cannabinoids (CBDA, CBD, CBG, CBN) from the cannabis plant while deliberately excluding or minimizing THC, the compound responsible for psychomimetic effects. This selective extraction allows the therapeutic components to be separated from the harmful components, achieving treatment of neurological disorders without adverse psychoactive effects
Solution Approach 2:
The patent applies different quality characteristics to different components of the cannabinoid composition. Each cannabinoid is present in specific optimized concentrations (CBDA: 40-60%, CBD: 10-30%, CBG: 5-20%, CBN: 1-10%) to maximize therapeutic benefits while minimizing side effects. This local optimization of composition ensures that each component contributes positively to the overall therapeutic effect without introducing harmful properties
2Reliability
If current treatments for neuroinflammation are used, then some inflammatory markers may be suppressed, but lack of efficacy and significant side effects limit their use
Solution Approach 1:
The patent creates a composite cannabinoid composition combining multiple cannabinoids (CBDA, CBD, CBG, CBN) in specific ratios. This composite approach leverages the synergistic effects of different cannabinoids, where each component contributes unique anti-inflammatory properties. The combination achieves superior anti-inflammatory efficacy compared to single cannabinoid treatments while maintaining a favorable side effect profile through the balanced composition
3Reliability
If THC-containing cannabis products are used to treat neurological disorders, then some therapeutic benefits may be achieved, but psychoactive effects and abuse potential increase
Solution Approach 1:
The patent systematically removes THC from the cannabinoid composition or limits it to trace amounts (<1%), extracting only the non-psychoactive therapeutic cannabinoids. This extraction approach preserves the therapeutic benefits for treating neurological disorders while eliminating the psychoactive effects and abuse potential associated with THC
Solution Approach 2:
The patent changes the compositional parameters of the cannabinoid mixture by optimizing the ratios of therapeutic cannabinoids (CBDA: 40-60%, CBD: 10-30%, CBG: 5-20%, CBN: 1-10%) while minimizing or eliminating THC. This parameter optimization ensures maximum therapeutic efficacy without psychoactive effects, fundamentally altering the risk-benefit profile of cannabinoid treatment
Data Source
AI summary
The present invention relates to compositions comprising cannabinoids. The present invention also relates to pharmaceutical compositions, dosage forms and methods of treating neurological disorders by administering the composition to a patient in need thereof.